Walker 1996.

Methods	Randomised controlled crossover trial of levodopa versus placebo Dropouts/withdrawals: PP (5) with premature discontinuations of 3 patients prior to start of trial
Participants	Included/analysed: 8/5 Demographics: 1 male, age 68.2 years Diagnosis: RLS according to Diagnostic Classification Steering Committee 1990 Setting: 1 centre in Canada No baseline values given
Interventions	Intervention: fixed single dose of 100 mg/25 mg levodopa/carbidopa for 1 week Control: fixed single dose of placebo capsules for 1 week Washout for 1 week between treatment periods
Outcomes	Objective quality of sleep: Change in sleep parameters (TST), PLMSI (using PSG) Safety: number of dropouts due to adverse events, number of patients with adverse events
funding source	The study was supported by the Kidney Foundation of Canada, Manitoba Branch, The Medical Research Council of Canada and Baxter Healthcare corporation.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Insufficient information.
Allocation concealment?	Unclear risk	Insufficient information.
Blinding? All outcomes	Low risk	Blinded scorers for PSG rating.
Incomplete outcome data addressed? All outcomes	Low risk	No incomplete outcome data.
Free of selective reporting?	Low risk	All results reported as prespecified with results of additional sleep parameters partly reported.
Free of other bias?	Low risk	Low indication of bias.